Logo Image
|Videos|December 16, 2016

Low Zika Virus Prevalence in Pregnant Women Tested in New York

Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, talks about prevalence of Zika in pregnant women in New York.

Daniel Eiras, MD, MPH, hospital epidemiologist at NYU Langone Medical Center, talks about prevalence of Zika in pregnant women in New York.

Interview Transcript (slightly modified for readability)

“Of the close to 500 patients that we screened for Zika, very few actually tested positive, less than 1%. It’s not clear why this is, it’s possible that most of the patients that we evaluated, at least early on, were Americans [who] were traveling on vacation and did not reside in Central and South America, and so their risk of exposure was actually quite low.

We also identified that the area in the hospital, or in the health system, that was most affected was really the outpatient obstetrics offices. We can target our resource allocation and education to those areas.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Read more